AWM
CMMB

Apollon Wealth Management’s Chemomab Therapeutics CMMB Stock Holding History

Apollon Wealth Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,000
Closed -$83K – 773
2021
Q4 		$83K Hold
3,000
– – 0.01% 741
2021
Q3 		$133K Buy
+3,000
New +$183K 0.02% 450

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Apollon Wealth Management's CMMB Position: Q1 2022 in Review

Apollon Wealth Management sold out of Chemomab Therapeutics (CMMB) in Q1 2022, closing a stake of 3,000 shares — an estimated $83K sold.

Apollon Wealth Management first reported a position in CMMB in Q3 2021 and held it in 2 quarters. The position peaked at $133K in Q3 2021. 16 funds tracked by Wall St. Rank hold CMMB as of Q1 2022.

  • Apollon Wealth Management reported no remaining Chemomab Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 3,000 Chemomab Therapeutics shares in Q1 2022, an estimated $83K.
  • Apollon Wealth Management first reported a position in Chemomab Therapeutics in Q3 2021 and held it in 2 quarters.
  • Apollon Wealth Management's Chemomab Therapeutics position peaked at $133K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2022.

Based on Apollon Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.